Skip to main content
OpenTrials
Completed

NCT Number: NCT02380911

Statins at the Primary Care Level

Hypercholesterolemia, a major cause of disease burden in both the developed and developing world, is estimated to cause 2.6 million deaths annually (4.5% of all deaths) and one third of ischemic heart diseases., and result in 29.7 million DALY lost. In Argentina, the prevalence of hypercholesterolemia increased between 2005 and 2013 from 27.9% to 29.8%, whereas the rate of non-optimal LDL-C, was 28.0%. The rate of high cholesterol awareness was 37.3 % and the proportion of those who are under pharmacological treatment was dismally low: only 11.1%. Furthermore, only one out of four subjects with a self-reported diagnosis of coronary heart disease (CHD) is taking statins. and most individuals with CHD who are on statins have sub-optimal LDL-C levels. Although other antihypertensive, antidiabetic and low-dose aspirin were available free-of-charge at the primary care clinics of the public sector, statins had not been included until recently. As of 2014, statins (simvastatin 20mg) were incorporated into the package of drugs provided free-of-charge for patients with high cholesterol, according to CVD risk stratification. The goal of this study is to test whether a multifaceted educational intervention targeting physicians and pharmacist assistants, improves detection, treatment and control of hypercholesterolemia among uninsured patients with moderate to high cardiovascular risk in Argentina. Specifically, the intervention will test whether a multifaceted educational intervention program lowers LDL-cholesterol levels and CVD risk in moderate to high cardiovascular risk patients, improves physician compliance with clinical practice guidelines, and improves patient care management and adherence to medication. A cost-effectiveness study will be conducted to compare the intervention to the usual standard of care. This randomized cluster trial will enroll 350 patients from 10 public primary care clinics who will be assigned to receive either the intervention or the usual care. This study is timely and will generate urgently needed data on effective and, practical and sustainable intervention programs aimed at the prevention and control of CVD risk that can be directly used in other primary care settings and health care systems in LMICs.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centro de Atención Primaria de la Salud "Dr. Favaloro", Puerto Madryn, Chubut Province, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Arteriosclerotic cardiovascular disease: defined as acute coronary syndrome; history of myocardial infarction, stable or unstable angina, coronary revascularization, stroke, or transient ischemic attack presumed to be of atherosclerotic origin and revascularization.
  • Moderate-High CVD risk according to the WHO charts adapted by the National MoH (estimated 10-year CVD risk ≥ 20%)
  • LDL-C level ≥ 190 mg/dL
  • Type 2 diabetes in patients between 40 and 75 years of age

Exclusion criteria

  • Patients that are already receiving statins, pregnant women, bed-bound, and patients who cannot give informed consent.
  • End stage chronics kidney disease receiving dialysis ,HIV/AIDS, tuberculosis, alcohol or drugs abuse.

Treatment and study plan

Educational Intervention

Other

Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.

In addition, 2 intervention support tools are used at the intervention clinics:

  • A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.
  • On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions.

Primary outcomes

  1. Cholesterol Level

    Time frame: 1 year

    Net change in LDL-C levels from baseline to month 12 between intervention and usual care groups among all study participants.

Secondary outcomes

  1. Global Cardiovascular Risk

    Time frame: 1 year

    Net change in 10-year-CVD Framingham risk score before and after the implementation of the program.

  2. Clinical practice guidelines compliance

    Time frame: 1 year

    Proportion of patients with high CVD risk who are on statins, and are receiving an appropriate dose according to the CPG.

  3. Cholesterol reduction

    Time frame: 1 year

    Proportion of patients with moderate-high CVD risk who have reduced 30% and 50% of their LDL-C, respectively.

  4. Treatment compliance

    Time frame: 1 year

    Level of treatment adherence evaluated through questionnaire.

  5. Costs of the intervention

    Time frame: 1 year

    Cost-effectiveness of the intervention program.

Other outcomes

  1. Cholesterol Level stratified by history of diabetes

    Time frame: 1 year

    Net change in LDL-C levels from baseline to month 12 between intervention and usual care groups stratified by history of diabetes.

  2. Global Cardiovascular Risk stratified by history of diabetes

    Time frame: 1 year

    Net change in 10-year-CVD Framingham risk score before and after the implementation of the program stratified by history of diabetes.

  3. Clinical practice guidelines compliance stratified by history of diabetes

    Time frame: 1 year

  4. Cholesterol reduction stratified by history of diabetes

    Time frame: 1 year

  5. Treatment compliance stratified by history of diabetes

    Time frame: 1 year

  6. Cholesterol level stratified by 10-year-CVD Framingham risk score level.

    Time frame: 1 year

  7. Clinical practice guidelines compliance stratified by 10-year-CVD Framingham risk score level.

    Time frame: 1 year

  8. Cholesterol reduction stratified by 10-year-CVD Framingham risk score level.

    Time frame: 1 year

  9. Treatment compliance stratified by stratified by 10-year-CVD Framingham risk score level.

    Time frame: 1 year

Sponsors and collaborators

Lead sponsor

Institute for Clinical Effectiveness and Health Policy

Other

Registry information

Official study title

An Educational Intervention to Improve Effectiveness in the Detection, Treatment and Control of Patients With High Cardiovascular Risk in Low-resource Settings in Argentina: Rationale and Study Design of a Cluster Randomized Controlled Trial.

Acronym: EPRINA

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Mar 5, 2015
Registry last updated
Aug 16, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.